Precision Optics Corporation received a $340,000 order for a single-use ophthalmic endoscope from a global medical device company.
Quiver AI Summary
Precision Optics Corporation, Inc. has announced a $340,000 production order from a major global medical device company for an initial batch of a new single-use ophthalmic endoscope, with production set to start in January 2025 and a product launch anticipated around June 2025. This order follows over five years of joint development and is expected to lead to additional orders to meet first-year demand post-launch. The new endoscope is designed to replace an existing reusable system, significantly enhancing image quality and offering single-use functionality, which may help increase market share for the customer. This order, alongside another significant order earlier this year for a cystoscope imaging assembly, marks a key milestone in Precision Optics' growth strategy focused on single-use endoscopy products. Overall, the company is optimistic about its fiscal year 2025 performance and has additional single-use programs in development.
Potential Positives
- Precision Optics Corporation secured a significant initial production order of $340,000 from a large global medical device company for a new single-use ophthalmic endoscope, indicating strong market demand for their products.
- The successful transition from development to production of this product, following five years of collaboration, highlights the company's capabilities and expertise in single-use medical technology.
- The company anticipates follow-on orders that may substantially increase revenue, positioning Precision Optics for growth in the fiscal year 2025.
- This order, along with a previous $9 million order for a different product, showcases the company's strategic focus on the growing single-use endoscopy market, potentially solidifying its competitive advantage in that sector.
Potential Negatives
- The production timeline indicates that the initial order won't contribute to revenue until after a significant delay, with production starting in January 2025 and the product launch anticipated in June 2025.
- The reliance on a large global medical device company for future orders raises concerns about over-dependence on a single customer for revenue growth.
- The press release outlines the need for ongoing follow-on orders to meet fiscal year 2025 revenue expectations, suggesting that initial orders may not be sufficient for stability or growth.
FAQ
What is the recent production order announced by Precision Optics?
Precision Optics announced a $340,000 order for a new single-use ophthalmic endoscope from a global medical device company.
When will production of the ophthalmic endoscope begin?
Production is scheduled to start in January 2025 and will continue for five months to support a product launch expected in June 2025.
What are the benefits of the new single-use ophthalmic endoscope?
The new endoscope offers significantly improved image quality and single-use functionality, replacing the current reusable system on the market.
How does this order impact Precision Optics' growth strategy?
This order aligns with Precision Optics' strategic plan for growth, marking a significant milestone in its transition to single-use endoscopy technology.
What future opportunities does Precision Optics see in single-use programs?
The company expects additional follow-on orders and significant revenue growth from multiple single-use programs currently in its product development pipeline.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$POCI Insider Trading Activity
$POCI insiders have traded $POCI stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $POCI stock by insiders over the last 6 months:
- MAHESH LAWANDE (Chief Operating Officer) purchased 1,726 shares.
- WAYNE M COLL (Chief Financial Officer) purchased 4,317 shares.
- JOSEPH NORMAN FORKEY (Chief Executive Officer) purchased 1,725 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$POCI Hedge Fund Activity
We have seen 12 institutional investors add shares of $POCI stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLEICHROEDER LP added 95,230 shares (+inf%) to their portfolio in Q3 2024
- NEEDHAM INVESTMENT MANAGEMENT LLC added 66,717 shares (+22.2%) to their portfolio in Q2 2024
- AMH EQUITY LTD added 41,000 shares (+32.7%) to their portfolio in Q3 2024
- MORGAN STANLEY added 27,777 shares (+96.5%) to their portfolio in Q2 2024
- GEODE CAPITAL MANAGEMENT, LLC added 25,530 shares (+95.5%) to their portfolio in Q3 2024
- MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. added 23,364 shares (+inf%) to their portfolio in Q3 2024
- JUNIPER INVESTMENT COMPANY, LLC added 15,502 shares (+inf%) to their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GARDNER, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced an initial $340,000 production order from a large, global medical device company to provide initial stocking quantities of a new single-use ophthalmic endoscope.
Production is scheduled to begin in January 2025 and proceed over the following five months, to provide starting inventory levels to support product launch currently expected to occur around June 2025. The Company expects follow-on orders to support first year requirements after launch with delivery rates two to three times those of this initial stocking order. The companies have previously entered into a licensing agreement that sets terms under which POC will manufacture the product or receive royalties if the product is manufactured by the customer or a third-party.
“This initial order is the culmination of more than five years of joint product development,” commented Dr. Joe Forkey, CEO of Precision Optics. “We expect either additional follow-on production orders that would be manufactured at POC facilities, or alternatively, royalties with similar bottom line economics should manufacturing be transferred to a non-POC facility. This product replaces our customer’s current re-usable endoscope-based system which has been on the market for over ten years. With the benefits of significantly improved image quality combined with single-use functionality, we believe this product will not only replace our customer’s existing product but has great potential to increase their market share in the ophthalmic market with the potential, over time, to be a significant opportunity for our customer and POC, in partnership.”
“This order, along with the $9 million, single-use cystoscope imaging assembly production order for another customer announced earlier this year, represents a significant milestone in POC’s strategic plan for future growth. For many years we have been developing technology and expertise to support the market shift to single-use endoscopy. These two products are the first of a number of programs in our product development pipeline that address the new design and manufacturing requirements for this high growth market segment. The transition of both of these programs to production this year further confirms the value of POC’s unique intellectual property and know-how in both the design and production of single-use endoscopes,” Dr. Forkey continued.
Production orders for both single-use programs represent incremental year-over-year revenue increases and are significant contributors to the Company’s optimism for fiscal year 2025 performance. More importantly, the successful development and transition to production of these two programs validates the investments the Company has made to position POC to become the provider of choice for single-use programs into the future.
“With multiple additional single-use programs in our product development pipeline and with a great response from potential new customers to our recent marketing messaging around this product category, we believe this is only the beginning of significant revenue growth driven by additional programs in this business area,” Dr. Forkey concluded.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions for the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit
www.poci.com
.
About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements which express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
[email protected]